Lymphoma CRO

With hundreds of subtypes of the disease, lymphoma represents one of the most complex areas of research in the medical field. Effectively understanding the impact of a therapy on a particular disease subtype requires in-depth analysis to determine biological drivers and propensities to affect disparate areas of the body, often representing only a small number of patients. Not surprisingly, enrollment for clinical trials compounds the logistical obstacles. Yet in recent years, drug developers have made enormous strides, conducting successful studies for targeted therapies that are showing promising results.

As a global leader in lymphoma with significant experience in B-cell, T-cell, follicular, Hodgkin’s, non-Hodgkin’s, and mantle cell lymphoma, Parexel has played a significant role in many of these advances. A key element of our success is deep expertise in patient enrollment specific to lymphoma trials, paired with an extensive site network and strategic mitigation plans to reduce operational risk. We combine extensive datasets, including site access, experience, unmet need, epidemiology, competition, and startup factors to determine the most effective country footprint. These strategies, along with patient-centric recruiting and retention practices, are informed by the strong relationships we maintain with patient advocacy groups specific to this therapeutic area.